The Wall Street Journal reported Wednesday morning that talks between Valeant Pharmaceuticals International (VRX) and Takeda Pharmaceuticals regarding the potential sale of Salix have broken down. Valeant will reportedly shift its focus to building Salix, rather than looking to sell it.
from RTT - Before the Bell http://ift.tt/2gbnMG7
via IFTTT
No comments:
Post a Comment